失代偿期肝硬化中的白蛋白:新概念与新视角
本文综述失代偿期肝硬化的病理生理背景,指出全身促炎和促氧化环境导致多器官功能障碍,并改变白蛋白分子结构与功能,损害其非胶体渗透压特性。白蛋白的胶体渗透压与非胶体渗透压特性使其成为潜在多靶点药物,长期输注可改善肝硬化腹水患者生存、预防并发症、简化腹水管理并减少住院,但结果不一,需进一步研究确认获益、最佳剂量与方案及优势人群。
要点
- 失代偿期肝硬化存在全身促炎促氧化状态,驱动多器官功能障碍。
- 白蛋白分子结构功能改变,非胶体渗透压特性受损。
- 长期白蛋白输注可能改善肝硬化腹水患者生存并减少住院。
核心结论
- 失代偿期肝硬化的全身促炎促氧化状态改变白蛋白分子,损害其非胶体渗透压特性,白蛋白作为多靶点药物有扩展应用前景。
- 长期白蛋白输注对肝硬化腹水患者可能改善生存、预防并发症、简化腹水管理并减少住院,但需进一步研究确认。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 失代偿期肝硬化以全身促炎促氧化环境为特征,主要因肠道细菌和/或细菌产物及损伤相关分子模式全身播散,激活免疫细胞释放促炎介质。
- 这些过程加剧导致慢加急性肝衰竭发生。
- 线粒体氧化磷酸化功能障碍导致全身细胞能量危机,促进多器官功能障碍和衰竭。
- 全身促炎促氧化状态导致白蛋白分子结构和功能改变,损害其抗氧化、清除、免疫调节和内皮保护等非胶体渗透压特性。
- 近期证据表明长期白蛋白输注可改善肝硬化腹水患者生存、预防并发症、简化腹水管理并减少住院。
临床怎么用
- 白蛋白的胶体渗透压和非胶体渗透压特性使其成为潜在多靶点药物,可扩展失代偿期肝硬化中白蛋白的适应证。
- 长期白蛋白输注可能用于肝硬化腹水患者以改善生存、预防并发症、简化腹水管理并减少住院。
- 需进一步研究确认白蛋白获益、明确最佳剂量和给药方案并识别最可能从长期白蛋白输注中获益的患者。
局限性
- 长期白蛋白输注结果存在差异,需进一步研究确认获益、最佳剂量与方案及优势人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure. A further mechanism promoting multiorgan dysfunction and failure likely consists with a mitochondrial oxidative phosphorylation dysfunction responsible for systemic cellular energy crisis. The systemic proinflammatory and pro-oxidant state of patients with decompensated cirrhosis is also responsible for structural and functional changes in the albumin molecule, which spoil its pleiotropic non-oncotic properties such as antioxidant, scavenging, immune-modulating and endothelium protective functions. The knowledge of these abnormalities provides novel targets for mechanistic treatments. In this respect, the oncotic and non-oncotic properties of albumin make it a potential multitarget agent. This would expand the well-established indications to the use of albumin in decompensated cirrhosis, which mainly aim at improving effective volaemia or preventing its deterioration. Evidence has been recently provided that long-term albumin administration to patients with cirrhosis and ascites improves survival, prevents complications, eases the management of ascites and reduces hospitalisations. However, variant results indicate that further investigations are needed, aiming at confirming the beneficial effects of albumin, clarifying its optimal dosage and administration schedule and identify patients who would benefit most from long-term albumin administration.
引用
- Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020. PMID: 32102926. doi:10.1136/gutjnl-2019-318843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。